Current stock page

Stock Analysis

Zymeworks Inc. (ZYME) Stock Analysis

Zymeworks Inc. (ZYME) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

ZYME Stock Analysis Summary

Zymeworks Inc. (ZYME) currently has an AIQ Score of 68/100, indicating a bullish setup. Momentum is the strongest factor at 78/100. Risk is the weakest current factor at 61/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

ZYME at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$26.24
AIQ Score68/100
Overall ViewBullish
Technical Analysis ConsensusSell
Market Cap$1.88B
P/E Ratio (TTM)39.16
Forward P/E—
EPS (Q3 FY2026)$2.43
Revenue (Q3 FY2026)$256.46M
Dividend Yield (TTM)0.00%
Beta0.78
Volume774.98K
52-week range$18.20-$31.97
RSI 1441.96
50-Day SMA$27.32
200-Day SMA$25.52
Analyst Price Target$42.60
Next EarningsMar 1, 2027
As of Nov 13, 2026 · Market close

ZYMEZymeworks Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$26.24−$0.23 (−0.87%)

Latest quote

  • Momentum
    78
  • Value
    66
  • Quality
    62
  • Risk resilience
    61
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

ZYME Stock Analysis Summary

Zymeworks Inc. (ZYME) currently has an AIQ Score of 68/100, indicating a bullish setup. Momentum is the strongest factor at 78/100. Risk resilience is the weakest current factor at 61/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, ZYME has AIQ Score of 68/100 with Momentum base of 78/100 and fading Risk resilience at 61/100. Wait for component alignment before adding exposure.

Healthcare · -0.87% stock move · ZYME classified in Biotechnology.

Current Evidence

BullishZYME is in a bullish AIQ regime; Momentum is the strongest visible factor at 78/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is ZYME Bullish or Bearish Right Now?

ZYME currently has a bullish overall setup. Momentum is the strongest factor at 78/100, while Risk Resilience is weakest at 61/100. The current evidence suggests a constructive setup.

Bull Case
  • - Momentum is constructive at 78/100.
  • - Analyst target implies +62.35% upside from the latest quote.
Bear Case
  • - Technical consensus has more sell votes than buy votes (29 vs 14).

Current Consensus

ZYME's Technical Analysis Consensus is currently Sell, with 14 buy, 3 neutral, and 29 sell votes. ZYME's 14-day RSI is 41.96, which places the stock in a weaker momentum range. ZYME's beta is 0.78, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in ZYME?

The largest recent change in ZYME is Value moving up by 24.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+9.0
Momentum
-5.0
Quality
+20.0
Risk
+2.0

What Would Change the ZYME Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

ZYME Decision Framework

Public evidence layers, setup checks, and risk context for Zymeworks Inc..

Zymeworks Inc. (ZYME) Stock Analysis

Zymeworks Inc. has an AIQ Score of 68/100 in a Bullish regime. Momentum is strongest at 78/100. Beta is 0.78, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextZYME is in a Bullish AIQ regime with score 68/100.
Signal ConflictThe primary conflict is that momentum leads at 78/100 while risk lags at 61/100.
Factor EvidenceMomentum 78/100 · Value 66/100 · Quality 62/100 · Risk 61/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 78/100.

TimingPass

Momentum is 78/100 and RSI (14) is 42.0.

Regime fitPass

ZYME is in a Bullish regime at 68/100.

Risk controlWait

Risk factor is 61/100 with beta 0.78 and annual volatility 54.03%.

ConflictPass

Current conflict: momentum leads at 78/100 while risk lags at 61/100.

AIQ Score
68/100
Price
$26.24
Beta
0.78
RSI (14)
42

ZYME Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

ZYME Fundamentals

ZYME valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$256.46M
Net income
$173.7M
Free cash flow
-$24.11M
View full ZYME fundamental analysis

ZYME Technical Analysis

ZYME technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Sell
RSI 14
41.96
Price vs SMA-50
-3.95%
View full ZYME technical analysis

ZYME Stock Catalysts

Track ZYME earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 1, 2027
Analyst target
$42.60
News items
5
View ZYME earnings and stock catalysts

ZYME Dividend Analysis

ZYME dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View ZYME dividend history and analysis

ZYME Financial Data

ZYME revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$256.46M
EPS
$2.43
Periods
8
View ZYME financials

ZYME Risk Analysis

ZYME volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.78
Risk score
61/100
1Y volatility
54.03%
View ZYME risk analysis

ZYME Stock News

ZYME stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read ZYME stock news

ZYME vs Biotechnology Peers

Current peer cohort: ZYME · ABCL · ABSI · ABUS · ABVX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
ZYME
Current stock
68/10066/10078/10061/1000.8454.03%Current
ABCL
AbCellera Biologics Inc.
64/10047/10089/10034/1001.7385.28%ZYME vs ABCL
ABSI
Absci Corporation
53/100—85/10030/1001.58104.15%ZYME vs ABSI
ABUS
Arbutus Biopharma Corp
70/10092/10051/10062/100-0.0945.89%ZYME vs ABUS
ABVX
Abivax S.A.
35/100—34/10037/1000.2486.44%ZYME vs ABVX
Pairwise Compare links: ABCL · ABSI · ABUS · ABVXZYME vs ABCLZYME vs ABSIZYME vs ABUSZYME vs ABVXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a ZYME stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for ZYME: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
39.16
As of Nov 13, 2026
Revenue growth
828.73%
Gross margin
98.29%
Current debt / equity
2.52
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$256.46M
Quarter net income
$173.7M
Quarter free cash flow
-$24.11M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
41.96
MACD
0.38

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
61/100
Beta
0.78
Annual volatility
54.03%
Max drawdown
-23.63%

ZYME Stock FAQ

What is ZYME stock price today?

Zymeworks Inc.'s current stock price is $26.24. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is ZYME bullish or bearish right now?

ZYME's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is ZYME's market cap?

ZYME's market cap is $1.88B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is ZYME's current P/E ratio?

ZYME's current P/E ratio is 39.16 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is ZYME's RSI?

ZYME's 14-day RSI is 41.96 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is ZYME above its 50-day and 200-day moving averages?

ZYME is -3.95% from its 50-day SMA and 2.81% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is ZYME's next earnings date?

ZYME's next earnings date is currently listed as Mar 1, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does ZYME pay a dividend?

ZYME's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.